Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clovis Oncology (CLVS)
NASDAQ:CLVS
Clovis Oncology (CLVS) Stock Price & Analysis
1,616 Followers
CLVS Stock Chart & Stats
Day’s Range$0.08 - $0.0977
52-Week Range― - ―
Previous Close$0.09
Volume24.52M
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding144,955,263
10 Day Avg. Volume15,445,470
30 Day Avg. Volume8,008,881
Standard Deviation0.58
R-Squared0.00041
Alpha-0.00290
Financial Highlights & Ratios
Price to Book (P/B)-0.02
Price to Sales (P/S)0.09
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering1
Clovis Oncology News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLVS FAQ
What was Clovis Oncology’s price range in the past 12 months?
Currently, no data Available
What is Clovis Oncology’s market cap?
Currently, no data Available
When is Clovis Oncology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Clovis Oncology’s earnings last quarter?
Currently, no data Available
Is Clovis Oncology overvalued?
According to Wall Street analysts Clovis Oncology’s price is currently Overvalued.
Does Clovis Oncology pay dividends?
Clovis Oncology does not currently pay dividends.
What is Clovis Oncology’s EPS estimate?
Clovis Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clovis Oncology have?
Currently, no data Available
What happened to Clovis Oncology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Clovis Oncology?
Among the largest hedge funds holding Clovis Oncology’s share is Gamco Investors, Inc. ET AL. It holds Clovis Oncology’s shares valued at 173K.
---
Clovis Oncology Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
CLVS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
---
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
Galera Therapeutics
―
MEI Pharma
―
SAB Biotherapeutics
―
Akebia Therapeutics
―
Applied Therapeutics
―
---